amphetamine use disorders michael j. mancino, m.d. university of arkansas for medical sciences ©...
TRANSCRIPT
![Page 1: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/1.jpg)
Amphetamine Use Disorders
Michael J. Mancino, M.D.
University of Arkansas for Medical Sciences
© AMSP 2011 1
![Page 2: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/2.jpg)
Substance Use/Problems %
Lifetime Substance Use → → →
• Alcohol: 80
• Cannabinoids: 40
• Cocaine: 15
• Amphetamine: 10
Lifetime Problems
60
50
50
60© AMSP 2011 2
![Page 3: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/3.jpg)
Why Problems Arise• Mimic medical/psych dx
• ↑ symptoms
• Direct side effects
• Occur in patient populations
• Recent ↑ in use© AMSP 2011 3
![Page 4: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/4.jpg)
This Talk Will Review
• History/nature of amphetamines
• Epidemiology
• Problems
• Treatment© AMSP 2011 4
![Page 5: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/5.jpg)
History• 1887- Amphetamine synthesized
• 1919 - Methamphetamine synthesized
• 1930’s – AMPH OTCOTC bronchodilator
• 1937 – AMPH prescription only
• 1939 – WWII troops, factory workers
• 1959 – FDA bans inhalers
• 1970 - AMPH Schedule II© AMSP 2011
5
![Page 6: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/6.jpg)
Drug Classification• Depressants:↑sleep, ETOH high, disinhibit
• Cannabinoids → ↓ drive, ↑ appetite
• Opioids → ↓ pain, ↓ cough
• Stimulants → ↑ energy/attention/activity© AMSP 2011 6
![Page 7: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/7.jpg)
Amphetamines• Routes of use
–Oral
–Nasal
–Intravenous
• Amphetamine high short-lived
–Drug half-life = 12-13 hours
–Post high letdown© AMSP 2011
7
![Page 8: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/8.jpg)
Amphetamines
© AMSP 2011 8
![Page 9: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/9.jpg)
StructureAdrenaline Amphetamine
© AMSP 2011 9
![Page 10: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/10.jpg)
Structure → Function• Adrenaline = Epinephrine
• “Fight or flight”
• Bind to sympathetic system
• Mobilize defense system–↑ glucose
–Shift blood© AMSP 2011 10
![Page 11: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/11.jpg)
How Neurons CommunicateNeurotransmitters are:
1. Synthesized in cell
2. Released
3. Bound to post-synaptic receptors
4. Recycled by transporters
5. Broken down by enzymes
6. Bound to pre-synaptic receptors
© AMSP 201111
1
2 4
3
56
![Page 12: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/12.jpg)
12© AMSP 2011 12
Effect of AMPH at the Synapse
DA-T
DAAMPH
DA-R
![Page 13: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/13.jpg)
© AMSP 2011 13
1. AMPH enters in exchange for DA
DA-T
DAAMPH
DA-R
![Page 14: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/14.jpg)
© AMSP 2011 14
2. AMPH enters pre-synaptic vesicles
DA-T
DAAMPH
DA-R
![Page 15: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/15.jpg)
© AMSP 2011 15
3. ↑ release of DA in pre-synapse
DA-T
DAAMPH
DA-R
![Page 16: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/16.jpg)
© AMSP 2011 16
4.↑ DA in pre-synapse and synapse
DA-T
DAAMPH
DA-R
![Page 17: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/17.jpg)
Medical Uses• Narcolepsy: sleep disorder
–Modafinil (Provigil)
–Armodafinil (Nuvigil)
• ADHD: developmental d/o–Amph/d-amphetamine (Adderall)
–Methylphenidate (Ritalin)© AMSP 2011 17
![Page 18: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/18.jpg)
This Talk Will Review
History/nature of amphetamines
• Epidemiology
• Problems
• Treatment© AMSP 2011 18
![Page 19: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/19.jpg)
Epidemiology• US lifetime use 2009 ≈ 10%
–Highest rate age 26-34 (>12%)
–Rate males = females
–Rate 2X white > black
• Past month use ≈ 0.5 %
• Lifetime dependence ≈ 1.5 %© AMSP 2011
19
![Page 20: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/20.jpg)
Drug Dependence• Presence of ≥ 3 in 12 months
– Tolerance– Withdrawal– Larger amounts– Desire/attempts to cut down– ↑ time spent– Give up activities– Ongoing use despite problems
© AMSP 2011 20
![Page 21: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/21.jpg)
Drug Abuse• Presence of ≥ 1 in 12 months
–Fulfill obligations
–Physically hazardous situations
–Legal consequences
–Interpersonal problems
Never dependent on this drug© AMSP 2011
21
![Page 22: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/22.jpg)
This Talk Will Review History/nature of amphetamines
Epidemiology
• Problems
• Treatment© AMSP 2011 22
![Page 23: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/23.jpg)
Amphetamine Problems• Medical
–Overdose–Withdrawal–Other
• Psychiatric–Psychosis–Anxiety/depression
© AMSP 201123
![Page 24: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/24.jpg)
Overdose
© AMSP 2011 24
Copyright © 2010 Meth Kills
![Page 25: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/25.jpg)
OD: Sympathetic Symptoms• ↑ heart rate (> 100 beats/min)
• ↑blood pressure (>160 /110)
• ↑ respiratory rate (>30/min)
• ↑ temperature (> 1020 F)
• Dilated pupils
• Seizures© AMSP 2011 25
![Page 26: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/26.jpg)
OD: Sympathetic Symptoms
• Chest pain / heart attack
• Stroke
• Arrhythmias = irregular heart beat
• Muscle rigidity → shock© AMSP 2011 26
![Page 27: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/27.jpg)
OD: Psychological Effects
• Restlessness
• Dizziness
• Irritable/violent
• Insomnia
• Higher doses →
–Suspiciousness
–Stereotypy
–Bruxism
–Punding© AMSP 2011 27
![Page 28: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/28.jpg)
OD Treatment• Basic life support (ABC’s)
• ↑ temp - dantroline (Dantrium): 1-2mg/kg
• Seizures (diazepam): 10mg IV
• ↑ BP- phentolamine (Regitine): 5-15mg
• Chest pains/heart attack
• Urine tox: ID other drugs© AMSP 2011 28
![Page 29: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/29.jpg)
Agitation Treatment• Benzodiazepines
• Diazepam (Valium): 10-30mg PO, 2-10 mg IV
• Lorazepam (Ativan): 2-4 mg PO, IM, IV
• Hi potency antipsychotics (anticholinergic SE)
• Haloperidol (Haldol): 5-10 mg PO, IM, IV
• Risperidone (Risperdal): 2-4 mg PO
© AMSP 2011 29
![Page 30: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/30.jpg)
Withdrawal• Begins ≥ 2 hrs, peaks day 1-2
• Symptoms opposite intoxication
– Sleepy, depressed, ↓ concentration, ↑ appetite
– Craving
• Symptoms ↓ over 3-4 days
• ↓ concentration/↑ sad last ≥ 2 months
© AMSP 201130
![Page 31: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/31.jpg)
Other Medical Problems• Infection (contaminated needles)
–Endocarditis (heart valve inflammation)
–Skin abcesses
–HIV → AIDS
• Intranasal → holes in nasal septum
• Heart attack
• Stroke (hemorrhagic or ischemic)© AMSP 2011 31
![Page 32: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/32.jpg)
Psychiatric
© AMSP 2011 32
![Page 33: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/33.jpg)
Stimulant Psychosis vs Schizophrenia
Stimulant Psychosis
• Labile mood
• Develops rapidly
• Physical findings
• Resolve days/wk
Schizophrenia
• Bland mood
• Develops slowly
• Rare findings
• Worsen with time© AMSP 2011 33
![Page 34: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/34.jpg)
Treatment • History, physical & labs
• Hospitalization
• Monitor vitals
• Behavioral
• Antipsychotics
• Avoid benzodiazepines
• Drug rehab© AMSP 2011 34
![Page 35: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/35.jpg)
Anxiety• Intoxication (mimic panic attacks)
– ↑ Heart rate, palpitations
– Nervousness, hyperventilation
• Obsessive-compulsive picture
– Take apart / reassemble mechanical objects
– High levels of use© AMSP 2011 35
![Page 36: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/36.jpg)
Depression• Related to withdrawal
• “Atypical depression”
– Impaired mood
– Sleepiness
– Excessive appetite
• Cessation → mood swings wks/mos© AMSP 2011 36
![Page 37: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/37.jpg)
Treatment Depression/Anxiety• Counseling
• Reassurance
• Medication rarely necessary
• Evaluate medical illness
– Heart attack, hyperthyroidism
• Rule out pre-existing disorders
– Major depression or anxiety
© AMSP 201137
![Page 38: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/38.jpg)
This Talk Will Review History/nature of amphetamines
Epidemiology
Problems
• Treatment© AMSP 2011 38
![Page 39: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/39.jpg)
Rehabilitation Goals• Drug free forever
• Interim goals to reduce
– Use
– HIV risk and other med issues
– Unemployment
– Crime
• Engage in treatment © AMSP 2011 39
![Page 40: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/40.jpg)
Rehabilitation Focus• Engage in treatment
• Support abstinence
• Prevent/reduce relapse
• Life management skills
• Cope with anxiety/stress© AMSP 2011 40
![Page 41: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/41.jpg)
Rehab Tools• Individual & group counseling
• Urine toxicology
• Psychosocial treatments– Contingency management
– Motivational interviewing
– Cognitive behavioral therapy (CBT)
– Self help groups
• Vocational rehab© AMSP 2011 41
![Page 42: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/42.jpg)
Medications
• Other substance use disorders
–Alcohol
–Opiates
• No efficacious meds for AMPH
© AMSP 2011 42
![Page 43: Amphetamine Use Disorders Michael J. Mancino, M.D. University of Arkansas for Medical Sciences © AMSP 20111](https://reader030.vdocuments.mx/reader030/viewer/2022032522/56649d6e5503460f94a4e9e9/html5/thumbnails/43.jpg)
Summary
• Amphetamine structure → action
• Amphetamine use common & serious
• Problems mimic med/psych problems
• Tx required for acute & chronic use
© AMSP 2011 43